Michigan Medicine launches first multi-site COVID-19 clinical trial on new national HERO registry
U-M was selected to participate in the first study to use the new national HERO registry. Led locally by Marisa Miceli, M.D., and Peter Higgins, M.D., Ph.D., M.Sc., this study focuses on how effective Hydroxychloroquine (HCQ) may be in protecting health care providers.
“The multi-site study will be large enough to definitively address questions such as ‘Can HCQ prevent COVID infections in health care providers (HCP)?’ or ‘Can HCQ reduce the severity of COVID infections in HCP?’” said David Williams, Ph.D., professor of anesthesiology and faculty lead of MICHR’s new Network-Based Research Unit (NBRU).
In supporting this first study, MICHR is facilitating rapid regulatory approval, contracting and budgets, with the help of the Ambulatory and Chronic Disease Clinical Trial Support Unit.
“This provider prevention study, with 15,000 health care providers nationwide, randomizes health care providers to HCQ vs. placebo,” said Peter Higgins, M.D., Ph.D., M.Sc.(CRDSA), professor, Division of Gastroenterology; director, IBD Program; and director, Ambulatory and Chronic Disease Clinical Trial Support Unit, Department of Internal Medicine. “We intend to identify whether HCQ can reduce infections in health care providers at high risk and reduce the severity of COVID-19 infections.”